Biomarker-Guided Antidepressant Selection (NCT07680140)
Biomarker-Guided Antidepressant Selection for Treatment-Resistant Depression
🩺 Plain-English Summary (8th-Grade Level)
Depression is one of the leading causes of disability worldwide. Common treatments like antidepressant medications and talk therapy work well for some people, but many others do not improve, even after trying multiple treatments. This study will investigate two alternative treatment options for people whose depression has not responded to standard treatments: repetitive transcranial magnetic stimulation (rTMS), a non-invasive form of brain stimulation, and ketamine, a fast-acting medication. It can be difficult to decide between these interventions in clinical practice, and selecting between them often comes down to patient preference and trial and error. This study is working to optimize the selection approach: using biological and behavioral markers to match each person to identify biomarkers that may predict response to rTMS or ketamine. Investigators believe that differences in how individuals respond to rTMS versus ketamine are partly explained by differences in how their brains are organized, and that these differences can be measured and used to guide intervention decisions. This is an early-stage pilot study designed to test whether this biomarker-based approach is practical and acceptable to patients. Investigators will evaluate how well a combination of brain imaging and clinical data can predict, at the individual level, who is likely to respond to rTMS versus ketamine. The ultimate goal is to develop a reliable, scalable tool that helps clinicians make faster and more informed intervention decisions, reducing the time people with treatment-resistant depression spend searching for an antidepressant that works.
Who can join: Review the eligibility criteria below.
Location: Weill Cornell Medicine — New York, New York
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Weill Cornell Medicine — New York, New York
📞 Contact the Study Coordinator
Phone: (646) 962-2900
Email: tmsinfo@med.cornell.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Depression - Major Depressive Disorder
- Racial Disparities in Antidepressant Treatment After a Psychiatric Consultation — Toronto, Ontario
- Sham-Controlled Rapid-Acting Neuromodulation for Depression — Sacramento, California
- Deaf CBT-TS to Reduce Suicide Risk — Rochester, New York
- Group PACBT for Depression — Los Angeles, California
- Closed-Loop Transcranial Alternating Current Stimulation for the Treatment of Major Depressive Disorder — Durham, North Carolina
- Teen Vulnerability to Irritability: Brain and Estrogen Changes — Chapel Hill, North Carolina
Explore by condition: All Depression - Major Depressive Disorder clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.